jimmy Turano

Biotech Busy with Bevy of Small Deals

Very good article and informative.
You may be the one and only expert in this field,
to give your personal insight on a particular stock.
'MRNA'
Nobody ever covers this stock, and yet they come out with dozens and dozens of news announcements, and analysts always issue a buy and high target prices.

Three Recent Biotech Activist Wins by Carl Icahn

Good Article! I am not surprised at all that 'MRNA' didn't make the list. In fact in 2 years I have never seen any coverage on 'MRNA'
on seeking alpha at all. Why? Especially puzzling, is in two years and up to 4 weeks ago, analysts still have high targeted stock prices.
Last target price was $4.00?. Again why? Investors some times are swayed by these analysts but must clearly understand that they follow the stock, therefore they seem to always show a bright side of great potential appreciation. If you check back since early 2007, they all have been wrong while the stock price has decreased in value. I bring this up, because shareholders are still being mislead today in the market. And if you reacted to the last target price of $4.00, just 4 weeks ago, you have seen once again the stock price go down. Nobody ever investigates these analysts.
They get paid and release new target prices that are not warranted.
Since it goes under the radar, I have brought it to light on seeking alpha for three straight years. Someone must have a voice or the continuing misinformation is fed to shareholders or potential shareholders who think they can get rich overnight.
I wish to thank SEEKINGALPHA for affording me the opportunity
to be heard on their site. September 1, 2009, 'MRNA' is on a weak downtrend and unless they announce a major partnership in the coming days, or a Reverse split, I only see a decreasing stock price regardless what analysts state in their news releases.
This is my opinion.

Amylin Has Yet to Crack Tough Diabetes Market

Dear Mr. Saadat,Your precise frank report on diabetes and amln is greatly appreciated. As an investor it is difficult to separate the froth & sometimes hype from research firms to make the proper decisions.
If as you say DIABETES IS A TOUGH MARKET, then how will biotech companies have a chance through RNAI in the next 10 years?
To me this is a gray area yet and may take a decade of testing and approvals. So when certain Biotech companies are solely dependent
on RNAI, promoting RNAI, doesn't the cost factor involved, and the time of potential approvals, far exceed the potential reward when companies are at their earliest stages?
Lastly, why do you think so many investors speculate huge amounts of money in companies that have failed in partnerships, failed in generating income, buy stocks when insiders sell the most stocks in a given year, buy into a stock just because it's down 85% from the year before, and have a blind eye to the research firms who have over touted over shot their target prices for several years in a row?
You and your article are rational in thinking, but others are just compulsive gamblers, and the SEC should post signs like at the Racetracks, that 'GAMBLING IS A DISEASE'.